bullish
IMNN: Translational Data from OVATION 2 Presented
On June 18, 2025, Imunon, Inc. (IMNN) announced the presentation of positive translational data from the Phase 2 OVATION 2 study of IMNN-001 at...
What is covered in the Full Insight:
- Introduction to Imunon, Inc.
- Translational Data from OVATION 2
- Details of OVATION 3 Trial
- Current Financial and Marketing Data
- Outlook and Valuation Analysis
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 8-minute read)
Related Insights
More »- IMNN: Translational Data from OVATION 2 Presented
- IMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers
- IMNN: First Site Activated for Phase 3 OVATION 3 Trial
- IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer
- IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025
Trending Collections
More »Trending Insights
More »Top Unpaywalled Insights
More »- [IO Technicals 2025/30] Iron Ore Rally Cools on Supply Surge, but Policy Hopes Keep Prices Afloat
- New Barbarians Podcast | Episode #029 | Recap & Reset: Macro Shifts, Ethereum's Spike, MicroStrat...
- Crypto Week Unleashes a Bitcoin Blitz and Sparks the Altcoin Catch-Up
- The Bunny Returns: Playboy’s Market Comeback
- HK Connect SOUTHBOUND Flows (To 18 July 2025); Volumes Strong, Net Buying Decent, Meituan Hot
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- IMNN: Translational Data from OVATION 2 Presented 20 Jun 2025
x